



15 JUNE 2023

Life Sciences Investor Update.

Upcoming events.

*FY results	March
*Valuation deep-dive	March
IP Group flagship science event	May
*Parkwalk meet the portfolio event	June
*AGM and life sciences investor update	June
*H1 results	August
*IP Group deeptech event	September
Kiko/McKinsey event	TBC
*IP Group cleantech event	TBC
*ESG deep-dive	TBC
*IP Group 'deeptech' conference (Asia)	2024

*Available to all shareholders



Investments with impact.

IP Group is a leading investor in breakthrough science and innovation companies with the potential to create a better future for all



Expertise.

Deep sector expertise built over many years



Impact.

Delivering social and environmental benefits, aligned with SDGs



International group.

Network of relationships in key territories



Permanent capital structure.

Advantages over fixed life fund model



Portfolio.

Built on access to leading science and technology




Track record.

3 unicorns created



Deep sector
expertise
with clear
focus areas.



Parkwalk is a wholly-own subsidiary of IP Group, retains its own investment committee.

**Inflection
points over
the next
12-18
months.**



istesso

GENOMICS

Life Sciences

Clinical trial progress
and revenue growth

GARRISON

FEATURE
SPACE



Technology

Revenue growth



Cleantech

Technical progress,
significant fundraisings
and new pipeline

Agenda.



09:30

Greg Smith
Intro

ip group
visionary ventures



09:35

Dr Sam Williams
Overview of Life
Sciences portfolio

ip group
visionary ventures



09:45

**Professor Sir
Peter Donnelly**

GENOMICS




10:00

Dr Gordon Sanghera
Q&A

**Oxford
NANOPORE**
Technologies

Healthcare costs vs time-to-intervention.




Healthcare costs vs time-to-intervention.



Risk factors for ASCVD.

Gender:	<div>Male</div> <div>Female</div>	Systolic BP:	<div>...</div> mmHg
Age:	<div>...</div> ▼ years	Receiving treatment for high blood pressure: (if SBP > 120mmHg)	<div>No</div> <div>Yes</div>
Race:	<div>White or other</div> ▼	Diabetes:	<div>No</div> <div>Yes</div>
Total Cholesterol:	<div>...</div> mg/dL	Smoker	<div>No</div> <div>Yes</div>
HDL Cholesterol:	<div>...</div> mg/dL		
<div>Reset</div>		<div>Calculate</div>	

Healthcare costs vs time-to-intervention.



Life Sciences investment strategy.



Understanding



Reprogramming



Reconditioning



Redirecting

Life Sciences investment strategy.



Understanding

GENOMICS



ieso



Reprogramming



Reconditioning



Redirecting

Life Sciences investment strategy.



Understanding

GENOMICS



ieso



Reprogramming

istesso

mission
therapeutics



Reconditioning



Redirecting

Life Sciences investment strategy.



Understanding

GENOMICS



ieso



Reprogramming

istesso

mission
therapeutics



Reconditioning



Redirecting

Life Sciences investment strategy.



Understanding

GENOMICS



ieso



Reprogramming

istesso

mission
therapeutics



Reconditioning



Redirecting

ieso

GENOMICS

Eight clinical readouts by 2025.

THERAPEUTICS PORTFOLIO	IP GROUP VALUE £m*	COMPANY	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
ONCOLOGY	18.3	artios ¹				
	18.7	Crescendo biologics				
	8.3	STORM THERAPEUTICS				
	21.2	AKAMIS BIO				
	12.3	IKSUDA THERAPEUTICS				
	16.1	microbiotica				
INFLAMMATION	95.6	istesso				
	18.1	mission therapeutics ²				
	15.9	Oxular ³				
	2.5	Kynos Therapeutics				
OTHER	14.7	PULMOCIDE INHALED RESPIRATORY MEDICINE				
	7.8	enterprise THERAPEUTICS				

* Based on valuation of IP Group's stake in company at 31/12/22, including debt where applicable.

1 Artios announced the initiation of Phase 2 trial in Feb 2023.

2 Mission Therapeutics announced the completion of Phase 1 trial in Jan 2023.

3 Oxular announced the acceptance of IND in Jan 2023.

GENOMICS

Unlocking Sustainable Personalised Healthcare

Company Overview

The next wave of genomics in healthcare will be for common diseases and will touch huge numbers of people around the world

First Wave

Genetics for Rare Diseases



Reactive: Aiding Diagnosis & Treatment

Genomic applications limited to **rare disease diagnosis** and **cancer treatment selection**, for **individuals**

Next Wave

Genomics for Common Diseases



Proactive: Widely Used in Prevention of Common Diseases & Cancers

Powerful risk stratification for common diseases and cancers gives effective targeting of **screening, prevention, & treatment programmes**, at **population scale**

Identifying disease risk better than any other factor


Genetics is a **major risk factor** for all the common diseases and cancers

For many of these diseases it is **the most important risk factor**, often **more predictive than all non-genetic risk factors combined**

Genetic risk for common diseases is due to the cumulative effects of large numbers of individual DNA changes: **polygenic risk**

Genetic Risk Scores: a **single test** measuring susceptibility to **many common diseases simultaneously**

Predictive Power of Risk Factors for Breast Cancer



Genetic Risk Scores Are The Best Single Method of Determining Susceptibility to Disease



The game-changer: we can now measure genetic risk for common diseases and avoid downstream acute care costs


A new set of tools now enables us to capture **polygenic risk** to measure an individual's **genetic risk for common diseases**

Genetic risk is a **very powerful predictor**: can **explain >20x difference in disease incidence**

Genetic risks can be measured, quantified, and acted on **years before symptom onset** and **expensive acute care costs**

Accurately predicting an individual's genetic susceptibility to disease

Coronary Artery Disease (men)




Genetic Risk Scores reveal large variations in disease incidence



Genomics plc has the best-performing and broadest polygenic risk offering

Comparison of Genomics' PRS with other published PRS (European ancestries)

Type 2 diabetes
 * Prostate cancer
 Alzheimer's disease
 Primary open angle glaucoma
 Hypertension
 * Breast cancer
 * Coronary artery disease
 Atrial fibrillation
 Systemic lupus erythematosus
 Melanoma
 Bowel cancer
 Chronic obstructive pulmonary disease
 Cardiovascular disease
 Osteoporosis
 Ischaemic stroke
 Non-alcoholic fatty liver disease
 Rheumatoid arthritis
 Age-related macular degeneration
 Lung cancer
 Major depressive disorder
 Chronic kidney disease
 Anxiety disorders



Commercial Organisations

- Genomics
- 23andMe**
- Genomic Prediction**
- Color Health**
- Allelica**

Specialist Academic Groups


- Khawaja 2018**
- Craig 2020**
- Ritchie 2021
- Coleman 2020
- Dai 2019
- Rutten 2018
- Said 2018
- Abraham 2019
- Schmit 2019
- Graff 2020
- Fritsche 2020
- Law 2020
- Potjer 2020
- Khera 2018
- Wang 2020
- Inouye 2018
- Wen 2016
- Shieh 2020
- Ho 2020
- Mavaddat 2019
- Mars 2020
- Chouraki 2016
- Najar 2021
- Zhou 2020
- Schumacher 2018
- Practical 2020
- Du 2019
- Conti 2021
- Mahajan 2018

Source: Genomics plc; company websites; media reports; academic publications
 Note: List non-exhaustive

Genomics plc PRSs cover more diseases than competitors and outperform specialist academic groups

Genomics plc tools are the most powerful in identifying variation in risk

Multiplier in disease incidence between High/Low Genetic Risk for Ten Selected Common Diseases



High variances in risk exist across many diseases, Genomics plc tools cover >50 diseases

Commercial opportunities across 3 customer segments leverage the same underlying technology



Enterprise

Double-digit \$m contract with US life insurer signed for delivery in 2023. Scaling-up now across key customer groups with large captive audience.

Customers

- Global Life Insurers & Reinsurers
- Large, Self-Insured Employers
- Employer Benefits Companies
- Executive Health Checks

TAM:

\$25+
Billion



Life Sciences

Applications

- Target / Indication Intelligence
- Clinical Development
- Commercial / Marketed Tx
- Companion Diagnostics (CDx)

TAM:

\$25+
Billion



Payers & Providers

A

Population Health
(Requires clinical & CE evidence)

B

Near-Term Revenue

- Single Payer Health Systems
- Value Based Care
- Reimbursement for Prevention
- Fee-for-Service Providers
- Companies Selling into Healthcare
- Health Test Providers

TAM:

\$50+
Billion

Successful NHS clinical trial establishes clinical utility

World-first trial, HEART, using Genomics risk assessment in cardiovascular disease prevention carried out with the NHS


Demonstrates **successful integration** of PRS into current GP (PCP) clinical practice

24% of participants had **clinically significant changes in CVD risk** when genetics added to QRISK in an integrated risk tool

GPs reported they would **change their management** of **13%** of the study population as a result of their integrated genetic risk

QRISK2 versus CVD IRT

832 participants



Implemented across England for 45-65 year olds, potential to avoid 18,560 acute events





Strong support from clinicians, key opinion leaders, and patients

“

“Advances in risk prediction have contributed to the significant fall we’ve seen in cases of heart and circulatory diseases in recent decades.

Personalised medicine, including incorporation of genetic tests, will be one of the defining advances of the coming decades.”

- Professor Sir Nilesh Samani, Medical Director British Heart Foundation

“The HEART study has shown us that this kind of genomic testing has the potential to transform the way we manage cardiovascular disease in primary care.

I changed my management of a number of my patients directly due to the new information coming through from the integrated tool.”

- Professor Ahmet Fuat, Chief Investigator HEART

NHS pilot

91% of healthcare providers found integration straightforward

87% of participants would recommend to friends & family





World first large scale roll out of genetic risk scores in healthcare

Our Future Health (OFH), the **flagship** UK programme with the NHS to recruit **5M participants** over 5 years

Genomics will be the **exclusive supplier** of Genetic Risk Tools in OFH

Risk information based on **Genomics plc Genetic Risk Tools provided to individuals and NHS**

Working with NICE to obtain **endorsement and scale-up** - a worldwide reference point



Deliver population level risk stratification and clinical benefits

Implemented across England for 45 to 65 year olds, we project:

700,000 hidden individuals would be identified as high risk for **CVD** - potentially avoiding **18,560 acute events**

350,000 women between 45-49 would be up-classified into moderate or high risk of **breast cancer** - 2X detection rate

Improved **bowel cancer** screening selection increases colonoscopy detection rate by **over 20%**

Lower use of costly DEXA scans for **osteoporosis** but **2X+** identified at high risk



Avoid 18,560 CVD Events



2X Detection Rates of Breast Cancer



2X Detection Rates of Osteoporosis




GENOMICS

Q&A



AGM
to start at 11am.



11:00AM 15 JUNE 2023

Annual General Meeting.

Resolutions.

- | | | | |
|-----|---|-----|--|
| 1. | Receive Report and Accounts for year ended 31 December 2022 | 11. | Re-elect Ms Aedhmar Hynes |
| 2. | Approve Directors' Remuneration Report | 12. | Re-elect Mr Greg Smith |
| 3. | Declare Final Dividend of £0.0076 per share for year ended 31 December 2022 | 13. | Re-elect Dr Elaine Sullivan |
| 4. | Re-appoint KPMG LLP as auditor | 14. | Authority to allot shares |
| 5. | Authorise Directors to fix the remuneration of the auditor | 15. | Disapplication of pre-emption rights |
| 6. | Elect Ms Anita Kidgell | 16. | Further disapplication of pre-emption rights |
| 7. | Re-elect Mr David Baynes | 17. | Political expenditure |
| 8. | Re-elect Dr Caroline Brown | 18. | Authorisation to make market purchases of own shares |
| 9. | Re-elect Mr Heejae Chae | 19. | To hold a general meeting on 14 clear days' notice |
| 10. | Re-elect Sir Douglas Flint | | |

Proxy Results.

Resolution	Votes For		Discretion		Votes Against		Votes Withheld
	Votes	%	Votes	%	Votes	%	Votes
1.	751,804,789	99.98	5,210	0.01	23,443	0.01	5,668,073
2.	643,182,974	85.98	5,210	0.01	104,756,327	14.01	9,557,004
3.	757,473,862	99.98	5,210	0.01	12,452	0.01	9,991
4.	752,186,188	99.29	5,210	0.01	5,267,200	0.7	42,917
5.	757,421,409	99.98	5,210	0.01	32,885	0.01	42,011
6.	731,943,382	96.64	5,210	0.01	25,401,836	3.35	151,087
7.	756,493,410	99.87	5,210	0.01	889,906	0.12	112,989
8.	749,334,751	98.93	5,210	0.01	8,049,464	1.06	112,090
9.	719,163,628	94.94	5,210	0.01	38,217,371	5.05	115,306
10.	741,853,880	97.94	5,210	0.01	15,525,370	2.05	117,055
11.	748,380,618	98.8	5,210	0.01	9,004,528	1.19	111,159
12.	756,776,091	99.91	5,210	0.01	610,176	0.08	110,038
13.	736,270,705	97.87	5,210	0.01	15,952,050	2.12	5,273,550
14.	750,475,454	99.07	5,210	0.01	6,960,298	0.92	60,553
15.	717,887,563	94.77	5,210	0.01	39,545,240	5.22	63,502
16.	697,420,347	92.07	5,210	0.01	60,011,259	7.92	64,699
17.	721,652,334	95.26	5,210	0.01	35,833,896	4.73	10,075
18.	750,528,521	99.1	5,210	0.01	6,776,371	0.89	191,413
19.	746,604,840	98.56	5,210	0.01	10,861,966	1.43	29,499

An aerial photograph of a surfer riding a wave, with a large, semi-transparent 'UP' watermark overlaid on the left side of the image. The text 'Thank you.' is centered in the middle of the image in a white, sans-serif font, with a small orange dot at the end of the sentence.

Thank you.